Analytical Data
-
Gene name
UNC13A
- Application
-
Alternative Names
Munc13-1 (KIAA1032)
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UPW8
-
Expression Region
1-340aa
-
Molecular Weight
43.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
UNC13A is a critical protein involved in synaptic transmission and neurotransmitter release, playing a pivotal role in the functioning of synapses in the nervous system. It is a member of the UNC13 protein family, which is essential for the priming of synaptic vesicles, a process that prepares these vesicles for rapid exocytosis in response to calcium influx during neuronal signaling. Research into UNC13A has gained significant attention due to its implications in neurological disorders, including its association with neurodegenerative diseases like Alzheimer’s and psychiatric conditions such as schizophrenia. Its role in synaptic homeostasis and plasticity makes it a potential target for therapeutic interventions aimed at enhancing synaptic function. Recent advancements in protein engineering techniques have allowed for the generation of recombinant UNC13A, enabling detailed structural and functional studies. These studies aim to elucidate the molecular mechanisms underlying UNC13A’s role in synaptic transmission, providing insights into how alterations in its function may contribute to disease pathology. Understanding UNC13A’s structure-function relationship will not only deepen our knowledge of synaptic physiology but may also pave the way for novel strategies to combat synaptic dysfunction in various neurodegenerative and psychiatric disorders.
